B
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S.,
“Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.”,
Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez,
“The use of monoclonal antibodies in the diagnosis of partially treated Pseudomonas aeruginosa meningitis: patient report.”,
Brazilian journal of medical and biological research = Revista brasileira de pesquisas médicas e biológicas / Sociedade Brasileira de Biofísica .. [et al.], vol. 19, no. 2, pp. 159-65, 1986.
L. E. Bermudez, Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., and Young, L. S.,
“Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.”,
Antimicrobial agents and chemotherapy, vol. 43, no. 8, pp. 1870-4, 1999.
L. E. Bermudez and Inderlied, C. B.,
“Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.”,
Microbial drug resistance (Larchmont, N.Y.), vol. 3, no. 3, pp. 277-82, 1997.
L. E. Bermudez, Young, L. S., and Enkel, H.,
“Interaction of Mycobacterium avium complex with human macrophages: roles of membrane receptors and serum proteins.”,
Infection and immunity, vol. 59, no. 5, pp. 1697-702, 1991.
L. E. Bermudez, Wagner, D., and Sosnowska, D.,
“Mechanisms of Mycobacterium avium pathogenesis.”,
Archivum immunologiae et therapiae experimentalis, vol. 48, no. 6, pp. 521-7, 2000.
L. E. Bermudez, Kemper, C. A., and Deresinski, S. C.,
“Dysfunctional monocytes from a patient with disseminated Mycobacterium kansasii infection are activated in vitro and in vivo by GM-CSF.”,
Biotherapy (Dordrecht, Netherlands), vol. 8, no. 2, pp. 135-42, 1994.
L. E. Bermudez, Petrofsky, M., and Stevens, P.,
“Treatment with recombinant granulocyte colony-stimulating factor (Filgrastin) stimulates neutrophils and tissue macrophages and induces an effective non-specific response against Mycobacterium avium in mice.”,
Immunology, vol. 94, no. 3, pp. 297-303, 1998.
L. E. Bermudez, Wu, M., Young, L. S., and Inderlied, C. B.,
“Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.”,
The Journal of infectious diseases, vol. 166, no. 4, pp. 923-6, 1992.
L. E. Bermudez, Wu, M., and Young, L. S.,
“Effect of stress-related hormones on macrophage receptors and response to tumor necrosis factor.”,
Lymphokine research, vol. 9, no. 2, pp. 137-45, 1990.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Chee, C. B., Aralar, P., Petrofsky, M., Parman, T., Green, C. E., Lewin, A. H., Ellis, W. Y., and Young, L. S.,
“Identification of (+)-Erythro-Mefloquine as an Active Enantiomer with Greater Efficacy than Mefloquine against Mycobacterium avium Infection in Mice.”,
Antimicrobial agents and chemotherapy, vol. 56, no. 8, pp. 4202-6, 2012.
L. E. Bermudez, Wu, M., Enkel, H., and Young, L. S.,
“Naturally occurring antibodies against Mycobacterium avium complex.”,
Annals of clinical and laboratory science, vol. 19, no. 6, pp. 435-43, 1989.
L. E. Bermudez, Sangari, F. J., Kolonoski, P., Petrofsky, M., and Goodman, J.,
“The efficiency of the translocation of Mycobacterium tuberculosis across a bilayer of epithelial and endothelial cells as a model of the alveolar wall is a consequence of transport within mononuclear phagocytes and invasion of alveolar epithelial cells.”,
Infection and immunity, vol. 70, no. 1, pp. 140-6, 2002.
L. E. Bermudez, Young, L. S., and Inderlied, C. B.,
“Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.